Xiamen Weijia Pharma Co., Ltd. was established in May 2017 as a "Double Hundred" main enterprise in Xiamen with a registered capital of 20 million RMB; The company focuses on the research and development, production of core intermediates and customized compounds for antiviral drugs, and has mature key technologies for the full range of intermediate production of Ritonavir and Lopinavir. Weijia Pharma has a total of 16 patents, with the non-homogeneous synthesis method and application of ritonavir intermediate being the core patents.
The headquarters of Weijia Pharma Co., Ltd. is located in Xiamen Haicang Biomedical Port, with a 4000 square meter standalone building, mainly responsible for RND, marketing, and administrative management;
Fujian Weijia Biopharm Co., Ltd. is a wholly-owned subsidiary of Xiamen Weijia Pharma Co., Ltd., located in Building 6, Xiaopai Road, Tieshan Town, Xinluo District, Longyan City (Tieshan Park, Longzhou Industrial Park, Fujian). It has a 100 ㎡ pilot plant and a 500 ㎡ scale-up production workshop, and has obtained GMP certificates for four veterinary drug varieties including Difloxacin Hydrochloride and Praziquantel. If you have any needs, please feel free to call our official email lzf@xmweijia.com ;  sales@xmweijia.com.